Table of Content

1 Research Methodology
2 Research Objectives
3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope Of The Study
4.3.1 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance
7 Introduction
7.1 Overview

8 Market Opportunities & Trends
8.1 Upcoming COVID-19 Vaccines
8.2 COVID-19 Vaccine Initiatives
8.3 Emergence of Next-Generation Vaccine Platforms

9 Market Growth Enablers
9.1 Faster Regulatory Approvals Of COVID-19 Vaccine
9.2 Rise In Number Of COVID-19 Patients
9.3 Contract Manufacturers Accelerating COVID-19 Vaccine Production

10 Market Restraints
10.1 COVID-19 Vaccine Distribution Among LMICs
10.2 Adverse Events & Negative Impact Of Approved Vaccines
10.3 Low Acceptance Of COVID-19 Vaccine

11 Market Landscape
11.1 Market Overview
11.2 COVID-19 Vaccine Pipeline
11.3 Market Size & Forecast
11.4 COVID-19 Supply Chain
11.5 Role of Contract Manufacturers in Manufacturing COVID-19 Vaccines
11.6 Five Forces Analysis
11.6.1 Threat of New Entrants
11.6.2 Bargaining Power of Suppliers
11.6.3 Bargaining Power of Buyers
11.6.4 Threat of Substitutes
11.6.5 Competitive Rivalry

12 Technology
12.1 Overview
12.2 Vector-Based COVID-19 Vaccine
12.2.1 Overview
12.3 Nucleic Acid-Based COVID-19 Vaccine
12.3.1 Overview
12.4 Protein-Based COVID-19 Vaccine
12.4.1 Overview
12.5 Whole Virus COVID-19 Vaccine
12.5.1 Overview

13 Geography
13.1 Market Snapshot & Growth Engine
13.2 Geographic Overview

14 APAC
14.1 Market Overview
14.2 Market Size & Forecast
14.3 Key Countries
14.3.1 China: Market Size & Forecast
14.3.2 India: Market Size & Forecast
14.3.3 Japan: Market Size & Forecast
14.3.4 South Korea: Market Size & Forecast
14.3.5 Australia: Market Size & Forecast

15 Europe
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 UK: Market Size & Forecast
15.3.2 Germany: Market Size & Forecast
15.3.3 Italy: Market Size & Forecast
15.3.4 France: Market Size & Forecast
15.3.5 Russia: Market Size & Forecast
15.3.6 Spain: Market Size & Forecast

16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast

17 Middle East & Africa
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Turkey: Market Size & Forecast
17.3.2 Saudi Arabia: Market Size & Forecast
17.3.3 Egypt: Market Size & Forecast
17.3.4 South Africa: Market Size & Forecast
17.3.5 UAE: Market Size & Forecast

18 Latin America
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Brazil: Market Size & Forecast
18.3.2 Mexico: Market Size & Forecast

19 Competitive Landscape
19.1 Competition Overview
19.1.1 AstraZeneca
19.1.2 Moderna
19.1.3 Gamaleya
19.1.4 Pfizer
19.1.5 Johnson &Johnson
19.1.6 GlaxoSmithKline
19.1.7 Novavax
19.1.8 Bharath Biotech
19.1.9 CureVac
19.1.10 Serum Institute of India
19.1.11 Sinovac
19.1.12 Sinopharm

20 Key Company Profiles
20.1 AstraZeneca
20.1.1 Business Overview
20.1.2 Product Offerings
20.1.3 Key Strategies
20.1.4 Key Strengths
20.1.5 Key Opportunities
20.2 GlaxoSmithKline
20.2.1 Business Overview
20.2.2 Product Offerings
20.2.3 Key Strategies
20.2.4 Key Strengths
20.2.5 Key Opportunities
20.3 Moderna
20.3.1 Business Overview
20.3.2 Product Offerings
20.3.3 Key Strategies
20.3.4 Key Strengths
20.3.5 Key Opportunities
20.4 Gamaleya
20.4.1 Business Overview
20.4.2 Product Offerings
20.4.3 Key Strategies
20.4.4 Key Strengths
20.4.5 Key Opportunities
20.5 Bharat Biotech
20.5.1 Business Overview
20.5.2 Product Offerings
20.5.3 Key Strategies
20.5.4 Key Strengths
20.5.5 Key Opportunities
20.6 Pfizer
20.6.1 Business Overview
20.6.2 Product Offerings
20.6.3 Key Strategies
20.6.4 Key Strengths
20.6.5 Key Opportunities
20.7 Johnson & johnson
20.7.1 Business Overview
20.7.2 Product Offerings
20.7.3 Key Strategies
20.7.4 Key Strengths
20.7.5 Key Opportunities
20.8 BioNTech
20.8.1 Business Overview
20.8.2 Product Offerings
20.8.3 Key Strategies
20.8.4 Key Strengths
20.8.5 Key Opportunities
20.9 CureVac
20.9.1 Business Overview
20.9.2 Product Offerings
20.9.3 Key Strategies
20.9.4 Key Strengths
20.9.5 Key Opportunities
20.10 Serum Institute of India
20.10.1 Business Overview
20.10.2 Product Offerings
20.10.3 Key Strategies
20.10.4 Key Strengths
20.10.5 Key Opportunities
20.11 Novavax
20.11.1 Business Overview
20.11.2 Product Offerings
20.11.3 Key Strategies
20.11.4 Key Strengths
20.11.5 Key Opportunities
20.12 Sinovac
20.12.1 Business Overview
20.12.2 Product Offerings
20.12.3 Key Strategies
20.12.4 Key Strengths
20.12.5 Key Opportunities
20.13 Sinopharm
20.13.1 Business Overview
20.13.2 Product Offerings
20.13.3 Key Strategies
20.13.4 Key Strengths
20.13.5 Key Opportunities

21 Upcoming Vendors
21.1 AnGes
21.1.1 Business Overview
21.2 AIVITABiomedical
21.2.1 Business Overview
21.3 CanSinoBio
21.3.1 Business Overview
21.3.2 Product Offerings
21.4 eubiologics
21.4.1 Business Overview
21.5 Genexine
21.5.1 Business Overview
21.6 GreenLight Bioscience
21.6.1 Business Overview
21.7 Gennova
21.7.1 Business Overview
21.8 Heat Biologics
21.8.1 Business Overview
21.9 INOVIO
21.9.1 Business Overview
21.10 IIBR
21.10.1 Business Overview
21.11 medicago
21.11.1 Business Overview
21.12 Symvivo
21.12.1 Business Overview
21.13 Valneva
21.13.1 Business Overview
21.14 Zydus Cadila
21.14.1 Business Overview

22 Report Summary
22.1 Key Takeaways
22.2 Strategic Recommendations

23 Quantitative Summary
23.1 Market By Geography
23.2 North America
23.3 Europe
23.4 APAC
23.5 Latin America
23.6 Middle East & Africa

24 Appendix
24.1 Abbreviations



List of Figures


List Of Exhibits
Exhibit 1 Global COVID-19 Vaccines Market
Exhibit 2 Market Size Calculation Approach 2021
Exhibit 3 Projected Manufacturing Capacity of Lead Companies Producing COVID-19 Vaccines by End of 2021 (in billions)
Exhibit 4 Impact of Upcoming COVID-19 Vaccine
Exhibit 5 Impact of COVID-19 Vaccine Initiatives
Exhibit 6 Impact of Emergence of Next-Generation Vaccine Platforms
Exhibit 7 Impact of Faster Regulatory Approvals of COVID-19 Vaccine
Exhibit 8 Impact of Rise in Number of COVID-19 Patients
Exhibit 9 COVID-19 Cases in Major Regions
Exhibit 10 Impact of Contract Manufacturers Accelerating COVID-19 Vaccine Production
Exhibit 11 Impact of COVID-19 Vaccine Distribution Among LMICs
Exhibit 12 Income Classification by Confirmed Doses Purchased ($ billions)
Exhibit 13 Impact of Adverse Events & Negative Impact of Approved Vaccines
Exhibit 14 Impact of Low Acceptance of COVID-19 Vaccine
Exhibit 15 People Not Willing to Take COVID-19 Vaccine (% share)
Exhibit 16 COVID-19 Vaccines Under Development by Dosage
Exhibit 17 COVID-19 Vaccines Under Development by Route of Administration
Exhibit 18 Global COVID-19 Vaccines Market 2021–2024 ($ billion)
Exhibit 19 COVID-19 Vaccine Logistics & Distribution
Exhibit 20 COVID-19 Vaccine Development 2021 (% share)
Exhibit 21 Five Forces Analysis 2021
Exhibit 22 Incremental Growth by Geography 2021 & 2024
Exhibit 23 Global COVID-19 Vaccines Market by Geography
Exhibit 24 Global COVID-19 Vaccines Market 2021- 2024 ($ million)
Exhibit 25 Global COVID-19 Vaccines Market 2021- 2024 (% share)
Exhibit 26 Production Capabilities of COVID-19 Vaccine Candidates Per Country (millions)
Exhibit 27 Income Classification by Confirmed Number of Doses Purchased by Country (Doses in billions)
Exhibit 28 APAC COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 29 COVID-19 Vaccines Market in APAC 2021–2024 ($ billion)
Exhibit 30 Incremental Growth in APAC 2021 & 2024
Exhibit 31 COVID-19 Vaccines Market in China 2021–2024 ($ million)
Exhibit 32 COVID-19 Vaccines Market in India 2021–2024 ($ million)
Exhibit 33 COVID-19 Vaccines Market in Japan 2021–2024 ($ million)
Exhibit 34 COVID-19 Vaccines Market in South Korea 2021–2024 ($ million)
Exhibit 35 COVID-19 Vaccines Market in Australia 2021–2024 ($ million)
Exhibit 36 Europe COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 37 COVID-19 Vaccines Market in Europe 2021–2024 ($ billion)
Exhibit 38 Incremental Growth in Europe 2021 & 2024
Exhibit 39 COVID-19 Vaccines Market in UK 2021–2024 ($ million)
Exhibit 40 COVID-19 Vaccines Market in Germany 2021–2024 ($ million)
Exhibit 41 COVID-19 Vaccines Market in Italy 2021–2024 ($ million)
Exhibit 42 COVID-19 Vaccines Market in France 2021–2024 ($ million)
Exhibit 43 COVID-19 Vaccines Market in Russia 2021–2024 ($ million)
Exhibit 44 COVID-19 Vaccines Market in Spain 2021–2024 ($ million)
Exhibit 45 North America COVID-19 Vaccine Market: Incremental Growth vs. Absolute Growth
Exhibit 46 COVID-19 Vaccine Developers in North America
Exhibit 47 COVID-19 Vaccines Market in North America 2021–2024 ($ billion)
Exhibit 48 Incremental Growth in North America 2021 & 2024
Exhibit 49 COVID-19 Vaccines Market in US 2021–2024 ($ million)
Exhibit 50 COVID-19 Vaccines Market in Canada 2021–2024 ($ million)
Exhibit 51 Middle East & Africa COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 52 COVID-19 Vaccines Market in Middle East & Africa 2021–2024 ($ billion)
Exhibit 53 Incremental Growth in Middle East & Africa 2021 & 2024
Exhibit 54 COVID-19 Vaccines Market in Turkey 2021–2024 ($ million)
Exhibit 55 COVID-19 Vaccines Market in Saudi Arabia 2021–2024 ($ million)
Exhibit 56 COVID-19 Vaccines Market in Egypt 2021–2024 ($ million)
Exhibit 57 COVID-19 Vaccines Market in South Africa 2021–2024 ($ million)
Exhibit 58 COVID-19 Vaccines Market in UAE 2021–2024 ($ million)
Exhibit 59 Latin America COVID-19 Vaccine Market: Incremental Growth versus Absolute Growth
Exhibit 60 COVID-19 Vaccine Market in Latin America 2021–2024 ($ billion)
Exhibit 61 Incremental Growth in Latin America 2021 & 2024
Exhibit 62 COVID-19 Vaccines Market in Brazil 2021–2024 ($ million)
Exhibit 63 COVID-19 Vaccines Market in Mexico 2021–2024 ($ million)
Exhibit 64 AstraZeneca Revenue 2017-2019 ($million)
Exhibit 65 AstraZeneca Research & Development Expenditure ($ million)
Exhibit 66 GlaxoSmithKline Revenue 2017-19 (billions)
Exhibit 67 Moderna Revenue 2017-2019 ($ million)
Exhibit 68 Moderna Research & Development Expenditure ($ million)
Exhibit 69 Pfizer Revenue 2017- 2019 ($ billion)
Exhibit 70 Pfizer Research & Development 2017- 2019 ($ billion)
Exhibit 71 Johnson & Johnson Revenue 2017- 2019 ($ million)
Exhibit 72 Johnson & Johnson Research & Development 2017- 2019 ($ million)
Exhibit 73 BioNTech Revenue 2017- 2019 (million)
Exhibit 74 BioNTech Research & Development 2017- 2019 ($ million)
Exhibit 75 Novavax Revenue 2017-2019 (million)
Exhibit 76 Novavax Research &Development Expenditure 2017-2019 (million)


List of Tables


List of Tables


Table 1 Key Caveats
Table 2 Currency Conversion 2013?2020
Table 3 Up-Coming COVID-19 Vaccines
Table 4 Comparison of Up-Coming COVID-19 Vaccine Platforms
Table 5 COVID-19 Cases in Top Ten Countries
Table 6 COVID-19 Vaccines EUA Approved as of Mid of 2021 January
Table 7 COVID-19 Vaccines Approved for Use in Various Countries
Table 8 COVID-19 Candidates in Clinical Phase Based on Vaccines Types
Table 9 List of COVID-19 Vaccines Under Phase II & III Clinical Trial
Table 10 List of COVID-19 Vaccines Under Phase I & II Clinical Trial
Table 11 List of COVID-19 Vaccines Under Phase I & Pre-Clinical Trial
Table 12 Key companies & CMOs Agreements for COVID-19 Vaccine (millions)
Table 13 EUA-Approved COVID-19 Vaccines
Table 14 COVID-19 Vaccines Based on Vector Platform Under Development
Table 15 COVID-19 Vaccines Based on Nucleic Acid Platform Under Development
Table 16 COVID-19 Vaccines Based on Protein Platform Under Development
Table 17 COVID-19 Vaccines Based on Whole Virus Platform Under Development
Table 18 Regional Confirmed COVID-19 Cases WHO (as of 2021 February)
Table 19 Countries with Highest COVID-19 Cases & Deaths
Table 20 List of Agreements Signed for COVID-19 Vaccines
Table 21 Approved Vaccines for COVID-19 in UK
Table 22 UK Agreement with Companies for COVID-19 Vaccine (million)
Table 23 List of Agreements Signed for COVID-19 Vaccines
Table 24 Approved Vaccines for COVID-19 in US
Table 25 US Agreement with Companies for COVID-19 Vaccine (million)
Table 26 List of Agreements Signed for COVID-19 Vaccines
Table 27 List of Agreements Signed for COVID-19 Vaccines.
Table 28 List of Agreements Signed for COVID-19 Vaccines with AstraZeneca
Table 29 List of Agreements Signed for COVID-19 Vaccines with Moderna
Table 30 List of Agreements Signed for COVID-19 Vaccines with Pfizer
Table 31 List of Agreements Signed for COVID-19 Vaccines with Johnson & Johnson
Table 32 List of Agreements Signed for COVID-19 Vaccines with GSK
Table 33 List of Agreements Signed for COVID-19 Vaccines with Novavax
Table 34 List of Agreements Signed for COVID-19 Vaccines with CureVac
Table 35 List of Agreements Signed for COVID-19 Vaccines with SinoVac
Table 36 AstraZeneca: Major Product Offerings
Table 37 GlaxoSmithKline: Major Product Offerings
Table 38 Moderna: Major Product Offerings
Table 39 Gamaleya: Major Product Offerings
Table 40 Bharat Biotech: Major Product Offerings
Table 41 Pfizer: Major Product Offerings
Table 42 Johnson & Johnson: Major Product Offerings
Table 43 BioNTech: Major Product Offerings
Table 44 CureVac: Major Product Offerings
Table 45 Serum Institute of India: Major Product Offerings
Table 46 Novavax: Major Product Offerings
Table 47 Sinovac: Major Product Offerings
Table 48 Sinopharm: Major Product Offerings
Table 49 CanSinoBio: Major Product Offerings
Table 50 Global COVID-19 Vaccines Market by Geography 2021?2024 ($ million)
Table 51 Global COVID-19 Vaccines Market by Geography 2021?2024 (%)
Table 52 North America COVID-19 Vaccines Market 2021?2024 ($ million)
Table 53 North America COVID-19 Vaccines Market 2021?2024 (%)
Table 54 Europe COVID-19 Vaccines Market 2021?2024 ($ million)
Table 55 Europe COVID-19 Vaccines Market 2021?2024 (%)
Table 56 APAC COVID-19 Vaccines Market 2021?2024 ($ million)
Table 57 APAC COVID-19 Vaccines Market 2021?2024 (%)
Table 58 Latin America COVID-19 Vaccines Market 2021?2024 ($ million)
Table 59 Latin America COVID-19 Vaccines Market 2021?2024 (%)
Table 60 Middle East & Africa COVID-19 Vaccines Market 2021?2024 ($ million)
Table 61 Middle East & Africa COVID-19 Vaccines Market 2021?2024 (%)